Rein Therapeutics Inc.
RNTX
$1.76
-$0.15-7.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -600.89% | 34.61% | -25.71% | 3.08% | -301.70% |
| Total Depreciation and Amortization | -- | -100.00% | -93.22% | 13.46% | 333.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7,209.65% | 55.83% | 117.33% | -66.52% | 140.86% |
| Change in Net Operating Assets | -163.42% | 581.61% | -86.34% | 145.97% | -32,190.91% |
| Cash from Operations | -26.00% | 54.48% | -59.15% | 49.27% | -533.60% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Investing | -- | -- | -- | -- | -117.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -- | -- | -- | -- |
| Cash from Financing | 100.22% | -102.44% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -100.00% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -12.83% | -143.19% | 287.35% | -200.51% | 577.60% |